Pembrolizumab Yields Strong Long-Term Survival in Advanced Melanoma

In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.

Long-term results of the KEYNOTE-001 trial found that 40% of patients with advanced melanoma treated with the anti–PD-1 antibody pembrolizumab were alive at 3 years, according to data presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago (abstract 9503).

In this video, Caroline Robert, MD, PhD, of the Institut Gustave Roussy in Paris, discusses these new results.